From Seoul: AimedBio is leveraging patient data and its expertise in antibody discovery and design to develop first-in-class antibody-drug conjugates with unique targets - the first program is FGFR3

CEO Nam-Gu Her describes the factors that make AimedBio unique in how it designs ADCs, and discusses how it landed on FGFR3 as its first target. While the company has at first focused on the antibody side, it is now also developing its own proprietary linker-payload combinations.

Recent Posts

See All

PureTech Health's CEO and Co-Founder discuss this week's IPF data, the approval of Cobenfy in schizophrenia, and the company's unique hub and spoke business model

Cardiff Oncology CEO Mark Erlander discusses last week's data for the PLK1 inhibitor onvansertib in first-line RAS-mutated mCRC

Syndax's CEO Michael Metzger talks about the approvals of Revuforj and Niktimvo, moving both into other settings, competition, and more

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh